In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO 2011: The Rapidly Changing Melanoma Market

Executive Summary

At the 2011 American Society of Clinical Oncology Annual Meeting in early June, Roche's vemurafenib, which is under review by the Food and Drug Administration and could be on the market by year's end, and Bristol-Myers Squibb Co.'s newly approved Yervoy took top billing, showcasing a rapidly evolving standard-of-care in metastatic melanoma.
Advertisement

Related Content

With The Launch Of Yervoy, Early Signs Of R&D Success For Bristol
With The Launch Of Yervoy, Early Signs Of R&D Success For Bristol
Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model
Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model
AZ and Merck: Moving Forward Cautiously
AZ and Merck: Moving Forward Cautiously

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003652

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel